arrow
S

Sami Ibrahimi

Helios Kliniken
H指数:15
被引数:2,434

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Epcoritamab monotherapy as outpatient treatment for patients with relapsed/refractory diffuse large B-cell lymphoma: Interim results from EPCORE NHL-6

Epcoritamab单药治疗门诊患者复发/难治性弥漫大B细胞淋巴瘤:EPCORE NHL-6研究的阶段性结果

2026-05-010
OAAI
Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM

TRANSFORM研究中lisocabtagene maraleucel在二线治疗大B细胞淋巴瘤中的长期生存情况

2026-05-010
PRE
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma

伊匹木单抗、纳武利尤单抗和 Brentuximab Vedotin 治疗复发霍奇金淋巴瘤的随机二期研究

Blood
IF23.1
2026-04-011
PRE
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen
2024-03-281
OAAI
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
LANCET
IF88.5
2022-06-01396
PRE
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
2018-11-12587
OAAI